<DOC>
	<DOCNO>NCT00284752</DOCNO>
	<brief_summary>Evaluate efficacy Abraxane first line chemotherapy patient hormone refractory metastatic prostate cancer , base prostate specific antigen ( PSA ) response</brief_summary>
	<brief_title>Phase II Trial Abraxane Front Line Therapy Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>Taxanes widely test effective chemotherapy drug hormone refractory prostate cancer . Weekly paclitaxel report produce 25-39 % PSA responses first line 33 % second line chemotherapy patient prostate cancer early clinical trial ( 1 , 2 ) . Paclitaxel activity prostate cancer schedule dependent , weekly paclitaxel report produce high response rate ( 1 , 2 ) . Docetaxel recently approve Food Drug Administration treatment hormone refractory metastatic prostate cancer , since chemotherapy drug document improvement survival group patient . Docetaxel associate 45.8 % overall grade 3/4 toxicity give steroid pre-medication . This regimen might difficult use advanced prostate cancer patient often elderly multiple co-morbid condition . ABI-007 [ Abraxaneâ„¢ ( paclitaxel protein-bound particle injectable suspension ) ( albumin-bound ) ] first class biologically interactive albumin-bound form chemotherapy ( 3 ) . This composition provide novel approach increase intra-tumoral concentration drug receptor-mediated transport process allow transcytosis across endothelial cell wall , thereby breach blood/tumor interface . This albumin-specific receptor mediate process involves bind specific receptor ( gp60 ) endothelial cell wall , result activation protein caveolin-1 , initiate open endothelial wall formation little cave caveolae , transport albumin-bound chemotherapeutic complex via caveolae underlie tumor interstitium ( 4 ) . A protein specifically secrete tumor ( SPARC ) bind entraps albumin , allow release hydrophobic drug tumor cell membrane . ABI-007 first biologically interactive albumin-bound chemotherapy agent leverage gp-60/caveolin-1/caveolae/Sparc pathway increase intra-tumoral concentration drug reduce amount toxic chemotherapy normal tissue . Preclinical study compare Abraxane paclitaxel demonstrate low toxicity , maximum tolerate dose ( MTD ) approximately 50 % high Abraxane ( 7 ) compare paclitaxel ( 11 ) . At equal dos le myelosuppression improve efficacy paclitaxel xenograft tumor model human mammary adenocarcinoma . Clinical study confirm improved toxicity profile high response rate , metastatic breast cancer , Abraxane compare cremophor EL paclitaxel ( Taxol ) ( 5 , 8 ) . The weekly regimen show active even patient cancer refractory paclitaxel , docetaxel Abraxane give agent ( 8 ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histopathologically cytologically proven adenocarcinoma prostate metastatic bone lymph node document bone scan CT scan evidence progression despite standard hormonal management ( orchiectomy , GNRH agonist , GNRH antagonisthormone refractory ) . No major organ allow 2 . No prior chemotherapy 3 . For patient antiandrogen therapy , patient must progressive disease antiandrogen withdrawal ( 6 week biclutamide nilutamide , 4 week flutamide ) . 4 . PSA progression define rise PSA . 1 . Active malignancy nonmelanoma skin cancer within 5 year enrollment . 2 . Significant active medical illness opinion investigator preclude treatment . 3 . Brain metastasis , nonbone metastasis except lymph node metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
</DOC>